Top Abstract Purchase Related
Home
>
Node
>
Subnode

Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Lipton, A.; Harvey, H.A.; Santen, R.J.; Boucher, A.; White, D.; Bernath, A.; Dixon, R.; Richards, G.; Shafik, A.

Cancer Research 42(8 Suppl): 3434s-3436s

1982

ISSN/ISBN: 0008-5472
PMID: 7044526
Document Number: 183792
We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

Document emailed within 1 workday
Secure & encrypted payments

Powles, T.J.; Gordon, C.; Coombes, R.C. 1982: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone Cancer Research 42(8 Suppl): 3458s-3460s
Gockerman, J.P.; Spremulli, E.N.; Raney, M.; Logan, T. 1986: Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial Cancer Treatment Reports 70(10): 1199-1203
Sutherland, C.M.; Muchmore, J.H.; Carter, R.D. 1985: Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer Southern Medical Journal 78(8): 987-989
Machin, D.; Andersen, K.W. 1997: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer Journal of the National Cancer Institute 89(9): 659-660
Chiesa, M.Dalla.; Passalacqua, R.; Michiara, M.; Franciosi, V.; Di Costanzo, F.; Bisagni, G.; Camisa, R.; Buti, S.; Tomasello, G.; Cocconi, G. 2007: Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial Acta Bio-Medica: Atenei Parmensis 78(3): 204-209
Sonoo, H.; Senoo, T.; Nishiki, M.; Morimoto, T.; Takashima, S. 1996: Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 447-454
Manni, A. 1987: Tamoxifen therapy of metastatic breast cancer Journal of Laboratory and Clinical Medicine 109(3): 290-299
Mustacchi, G.; Milani, S.; Pluchinotta, A.; De Matteis, A.; Rubagotti, A.; Perrota, A. 1994: Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly Anticancer Research 14(5b): 2197-2200
Israël, L.; Hajji, O.; Grefft-Alami, A.; Desmoulins, D.; Succari, M.; Cals, M.J.; Miocque, M.; Bréau, J.L.; Morère, J.F. 1985: Vitamin A augmentation of the effects of chemotherapy in metastatic breast cancers after menopause. Randomized trial in 100 patients Annales de Medecine Interne 136(7): 551-554
1988: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women New England Journal of Medicine 319(26): 1681-1692
Boel, K.; Van Poppel, H.; Goethuys, H.; Derluyn, J.; Vandenbroucke, F.; Popelier, G.; Casselman, J.; Billiet, I.; Vanuytsel, L.; Paridaens, R.; Baert, L. 1999: Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial Anticancer Research 19(3b): 2157-2161
Gershanovich, M.L.; Garin, A.M.; Baltinia, D.; Kurvet, A.; Kangas, L.; Ellmen, I. 1997: Results of phase Ii clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women Voprosy Onkologii 43(6): 587-595
Rosselli Del Turco, M.; Palli, D.; Cariddi, A.; Ciatto, S.; Pacini, P.; Distante, V. 1994: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up JAMA 271(20): 1593-1597
Nicholson, B.; Paul, D.; Shyr, Y.; Garrett, M.; Hande, K.R.; Johnson, D.H. 1997: Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase Ii trial Seminars in Oncology 24(4 Suppl 11: S11
Carpenter, J.T.; Raney, M.; Logan, T. 1986: Phase Ii evaluation of procarbazine in metastatic breast cancer: a Southeastern Cancer Study Group Trial Cancer Treatment Reports 70(5): 679-680
Secginli, S.; Nahcivan, N.O. 2011: The effectiveness of a nurse-delivered breast health promotion program on breast cancer screening behaviours in non-adherent Turkish women: A randomized controlled trial International Journal of Nursing Studies 48(1): 24-36
Pannuti, F.; Martoni, A.; Piana, E.; Tomasi, L.; Grieco, A.; Farris, A.; Saccani, F.; Baroni, M. 1984: Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(4): 211-215
Kondo, M.; Itani, K.; Yoshikawa, T.; Tanaka, Y.; Watanabe, N.; Hiraoka, M.; Noguchi, M.; Miura, K. 1995: A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(12): 1807-1811
Kühböck, J.; Ludwig, H.; Pötzi, P.; Zielinski, C. 1985: Aminoglutethimide therapy in advanced breast cancer Wiener Medizinische Wochenschrift 135(23-24): 608-611
Follézou, J.Y.; Palangie, T.; Feuilhade, F. 1987: Randomized trial comparing mitoxantrone with adriamycin in advanced breast cancer Presse Medicale 16(16): 765-768